Clinical Pharmacokinetics of the Anti-Interleukin-20 Monoclonal Antibody NNC0109-0012 in Healthy Volunteers and Patients with Psoriasis or Rheumatoid Arthritis

Advances in Therapy

Volumn 32, Issue 3, 2015, Pages 228-238

  Lundblad, Mia Sandberg ^a   Overgaard, Rune Viig ^a   Göthberg, Marie ^a   Fjording, Marianne Scheel ^a   Watson, Estelle ^a  

^a NOVO NORDISK A S   (Denmark)

Author keywords

Chronic plaque psoriasis; Monoclonal antibodies; NNC0109 0012; Pharmacokinetics; Rheumatoid arthritis

Indexed keywords

FLETIKUMAB; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY;

ADULT; AREA UNDER THE CURVE; ARTHRITIS, RHEUMATOID; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; FEMALE; HALF LIFE TIME; HUMAN; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PSORIASIS; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; AREA UNDER CURVE; ARTHRITIS, RHEUMATOID; BODY WEIGHT; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HALF-LIFE; HEALTHY VOLUNTEERS; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; PSORIASIS;

EID: 84936928734     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-015-0191-7     Document Type: Article

References (22)

1. Blumberg H, Conklin D, Xu WF, et al. Interleukin 20: discovery, receptor identification, and role in epidermal function. Cell. 2001;104(1):9–19.
2. Wang F, Lee E, Lowes MA, et al. Prominent production of IL-20 by CD68+/CD11c+ myeloid-derived cells in psoriasis: gene regulation and cellular effects. J Invest Dermatol. 2006;126(7):1590–9.
3. Wolk K, Kunz S, Asadullah K, et al. Cutting edge: immune cells as sources and targets of the IL-10 family members? J Immunol. 2002;168(11):5397–402.
4. Dumoutier L, Leemans C, Lejeune D, et al. Cutting edge: STAT activation by IL-19, IL-20 and mda-7 through IL-20 receptor complexes of two types. J Immunol. 2001;167(7):3545–9.
5. Logsdon NJ, Deshpande A, Harris BD, et al. Structural basis for receptor sharing and activation by interleukin-20 receptor-2 (IL-20R2) binding cytokines. Proc Natl Acad Sci. 2012;109(31):12704–9.
6. Hsu YH, Li HH, Hsieh MY, et al. Function of interleukin-20 as a proinflammatory molecule in rheumatoid and experimental arthritis. Arthritis Rheum. 2006;54(9):2722–33.
7. Hsu YH, Chang MS. Interleukin-20 antibody is a potential therapeutic agent for experimental arthritis. Arthritis Rheum. 2010;62(11):3311–21.
8. Kragstrup TW, Otkjaer K, Holm C, et al. The expression of IL-20 and IL-24 and their shared receptors are increased in rheumatoid arthritis and spondyloarthropathy. Cytokine. 2008;41(1):16–23.
9. Rømer J, Jackerott M, Mandelbaum J, et al. Expression of interleukin-20 and its receptor chains IL-20R1, IL-20R2 and IL-22R in synovium from patients with rheumatoid arthritis. Ann Rheum Dis. 2012;71(suppl 3):646.
10. Pass J, Clausen JT, Worsaae A, et al. Characterization of a human monoclonal antibody that neutralizes interleukin-20. Ann Rheum Dis. 2012;71(suppl 3):642.
11. Šenolt L, Göthberg M, Valencia X, et al. Efficacy and safety of NNC0109-0012 (anti-IL-20 mAb) in patients with rheumatoid arthritis: results from a phase 2a trial. Ann Rheum Dis. 2012;71(suppl 3):152.
12. Al Kotbi N, Jensen L, Graff LB. FRI0196 NNC0109-0012 (anti-IL-20 MAB), well tolerated in healthy subjects and patients with rheumatoid arthritis. Ann Rheum Dis. 2013;71(suppl 3):379.
13. Leszczynski P, Eshof M, Stegmann H, et al. FRI0197 NNC0109-0012 (anti-IL-20 mAb), well tolerated in patients with rheumatoid arthritis. Ann Rheum Dis. 2012;71(suppl 3):379–80.
14. US Department of Health and Human Services Food and Drug Administration. Guidance for industry: bioanalytical method validation. 2001 [cited 2014 February 4]. Available from: www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm070107.pdf.
15. DeSilva B, Smith W, Weiner R, et al. Recommendations for the bioanalytical method validation of ligand-binding assays to support pharmacokinetic assessments of macromolecules. Pharm Res. 2003;20(11):1885–900.
16. Viswanathan CT, Bansal S, Booth B, et al. Quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays. Pharm Res. 2007;24(10):1962–73.
17. Mascelli MA, Zhou H, Sweet R, et al. Molecular, biologic, and pharmacokinetic properties of monoclonal antibodies: impact of these parameters on early clinical development. J Clin Pharmacol. 2007;47(5):553–65.
18. Aydogdu E, Pamuk ON, Donmez S, et al. Decreased interleukin-20 level in patients with systemic sclerosis: are they related with angiogenesis? Clin Rheumatol. 2013;32(11):1599–603.
19. Michalak-Stoma A, Bartosinska J, Kowal M, et al. Serum levels of selected Th17 and Th22 cytokines in psoriatic patients. Dis Markers. 2013;35(6):625–31.
20. van Dooren FH, Duijvis NW, te Velde AA. Analysis of cytokines and chemokines produced by whole blood, peripheral mononuclear and polymorphonuclear cells. J Immunol Methods. 2013;396(1–2):128–33.
21. Chirmule N, Jawa V, Meibohm B. Immunogenicity to therapeutic proteins: impact on PK/PD and efficacy. AAPS J. 2012;14(2):296–302.
22. Thway TM, Magana I, Bautista A, et al. Impact of anti-drug antibodies in preclinical pharmacokinetic assessment. AAPS J. 2013;15(3):856–63.